Eli Lilly, Novo Nordisk get growth stock status on weight-loss drug boost
(Repeats Feb 16 story with no changes to text) By Medha Singh and Manas Mishra (Reuters) – U.S.-based Eli Lilly and Denmark’s Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks. Retail and institutional investors alike have flocked to…